Economic Impact of Targeted and Immunotherapies in Treating Operable Esophageal and Non-Small Cell Lung Cancers
Immune and targeted therapy in operable thoracic patients is associated with a significant cost burden. Studies are needed to assess cost-effectiveness to ensure optimal resource allocation and improve patient outcomes.
Authors
- Viengneesee Thao (ORCID: https://orcid.org/0000-0003-2136-3540)
- Bijan J. Borah (ORCID: https://orcid.org/0000-0002-4526-462X)
- Yahya Alwatari (ORCID: https://orcid.org/0000-0002-0219-3251)
- Mohamed Shanshal (ORCID: https://orcid.org/0009-0005-0775-2680)
- Sameh Taki Aldin
- Nate C. Johnson
- Kimberly Shen
Institutions
- Mayo Clinic (US)
- Mayo Clinic in Arizona (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- Annals of Thoracic Surgery Short Reports
- Published
- 2025-02-05
- DOI
- https://doi.org/10.1016/j.atssr.2025.01.008
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00